Seppo Yl News Today

This month marks 15 years since PLOS ONE published its first papers. As we celebrate this milestone, we invited authors of some of the first papers to be published, as well as an author of a more recent paper, to share information about their careers, their perspectives on Open Science, and their experiences as PLOS ONE authors.

 E-Mail IMAGE: The researchers analysed the contribution of the five main cell types involved in coronary artery disease. view more  Credit: UEF/Raija Törrönen Using single cell technology, a new study sheds light on the significance of genetic risk factors for, and the diversity of cells involved in, the development of coronary artery disease. The researchers analysed human atherosclerotic lesions to map the chromatin accessibility of more than 7,000 cells. The chromatin accessibil...

Researchers at the University of Eastern Finland have uncovered potential mechanisms by which microRNAs (miRNA) drive atherogenesis in a cell-type-specific manner. Published in the Arteriosclerosis, Thrombosis, and Vascular Biology journal, the study provides novel insight into the miRNA profiles of the main cell types involved in atherosclerosis.

New technologies are expected to enhance nasal vaccines industry growth as particular attention is being paid to designing delivery strategies that take into account the broad range of diseases, populations and healthcare delivery settings that will benefit from the mucosal route of delivery. Key challenges for the nasal vaccines industry includes translating in vivo data to clinical outcomes

State support for a Finnish Covid nasal spray comes up short. Finnish nasal spray vaccine firm continues its search for investors. Image: Janne Järvinen / Yle A Finnish Covid vaccine company says it risks private investors withdrawing from the endeavour after the state investment agency Business Finland said it would not cover the full cost of a clinical trial. In April, Rokote Laboratories Finland, the company that developed the vaccine, applied for a grant from the public financier that woul...

Date Time HiLIFE director Olli Silvennoinen appointed as director of Biocenter Finland Olli Silvennoinen will start his new appointment on 1st of May. He has worked as director of HiLIFE from April 2019. The rectors of Biocenter Finland partner Universities have nominated HiLIFE director, professor Olli Silvennoinen as new director of Biocenter Finland. Silvennoinen will start his new appointment on 1 May 2021. Silvennoinen has worked as director of HiLIFE at the University of Hels...

Aleksi Teivainen Share The vaccine is based on research undertaken by the University of Helsinki and the University of Eastern Finland. It takes advantage of a clinically proven gene transfer technology developed under the tutelage of Seppo Ylä-Herttuala, an academy professor at the University of Eastern Finland. It triggers an immune response by prompting nasopharyngeal cells to produce the virus protein with a safe adenovirus carrier containing a cloned DNA str...

Finnish nasal vaccine firm scrambles for financing The professors behind an open source nasal vaccine say that the effort needs tens of millions of euros in funding. Securing funding for the final phase of the coronavirus nasal vaccine is proving to be difficult, says Kalle Saksela, one of the professors developing the vaccine. Image: Markku Ulander / Lehtikuva The researchers behind a nasally-administered coronavirus vaccine under development in Finland say time is running out to get their pro...

New academic spin-out based in Finland introduces a nasal spray vaccine against COVID Mar 8 2021 Rokote Laboratories Finland Ltd., a newly-founded academic spin-out based in Finland is working to develop and introduce to the markets a nasal spray vaccine against COVID. The vaccine is based on research carried out at the University of Helsinki and the University of Eastern Finland. Image Credit: University of Eastern Finland The vaccine uses gene transfer technology developed at the University o...

As they seek funding, the researchers say more vaccines are needed to combat new variants of the contagious virus.